盐酸帕罗西汀对帕金森病患者合并抑郁和焦虑症状的临床疗效  

Clinical Efficacy of Paroxetine Hydrochloride in the Treatment of Parkinson's Disease Patients with Depression and Anxiety Symptoms

作　　者：晋艳[1] JIN Yan(Department of Neurology,Wuxi People's Hospital,Wuxi 214000,China)

机构地区：[1]江苏省无锡市人民医院神经内科,江苏无锡214000

出　　处：《中国医药指南》2023年第34期95-97,共3页Guide of China Medicine

摘　　要：目的探讨在帕金森病患者合并抑郁和焦虑的治疗中选择盐酸帕罗西汀的价值。方法对2020年1月至2022年10月在本院确诊为帕金森病合并抑郁与焦虑的62例患者的病历资料进行回顾性分析,以随机数字表法分两组,其中31例接受常规方案治疗(对照组),31例接受盐酸帕罗西汀治疗(观察组)。比较两组临床疗效、不良反应发生率、临床指标等。结果与对照组比,观察组临床总有效率较高(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05);治疗后,两组MoCA评分升高,UPDRS评分、HAMD评分、HAMA评分降低,且观察组低于对照组(P<0.05)。结论选择盐酸帕罗西汀治疗伴有抑郁和焦虑的帕金森病可改善患者的帕金森症状,同时缓解其身心压力。Objective To explore the value of selecting paroxetine hydrochloride in the treatment of Parkinson's disease patients with depression and anxiety.Methods The medical records of 62 patients diagnosed with depression and anxiety from January 2020 to October 2022.Furthermore,31 were treated with conventional regimen(control group)and 31 were paroxetine hydrochloride(observation group).The clinical efficacy,incidence of adverse reactions and clinical indicators of the two groups were compared.Results Compared with the control group,the observation group had higher clinical response rate(P<0.05);there was no significant difference in the incidence of adverse effects(P>0.05);after treatment,the MoCA scores increased,the UPDRS,HAMD and HAMA scores decreased,and the observation group was lower than the control group(P<0.05).Conclusions Paroxetine hydrochloride is chosen to treat PD associated with depression and anxiety,which can improve Parkinson's symptoms and relieve their physical and mental stress.

关 键 词：帕金森病 抑郁 焦虑 药物治疗 

分 类 号：R749[医药卫生—神经病学与精神病学]